regression) almost exclusively due to increased risk of periprocedural myocardial infarction (MI) (1.6% vs. 0.2%; p=0.050), while the rates of cardiac death, spontaneous MI, and target lesion revascularization did not differ significantly between the two groups.

Conclusion: The adjunctive use of IVUS during PCI in the EXCELLENT trial was associated with more stents implanted, longer stenting, and bigger stenting. There were no significant advantages of IVUS guidance regarding clinical outcome, but rather a significant increase in periprocedural enzyme elevation, reflecting the more aggressive procedures performed with IVUS guidance.

TCT-105 Impact of Tissue Prolapse on Short- and Long-Term Clinical Outcomes after Stent Implantation in Patients with Acute Myocardial Infarction: An Intravascular Ultrasound Analysis

Young-Joon Hong1, Myung Ho Jeong2, Seung Uk Lee3, Gun Ha Choi4, Jin-A Song2, Dong Han Kim5, Ki Hong Lee6, Min Goo Lee7, Keun Ho Park8, Doo Sun Sim9, Ju Han Kim10, Youngkuem Ahn1, Jeong Gwan Cho1, Jung Chae Park2, Chonnann National University Hospital, Gwangju, Republic of Korea; 2Kwang Ju University, Kaesoo, Republic of Korea; 3Chonnam National University Hospital, Gwangju, Republic of Korea; 4Kwangju Christian Hospital, Gwangju, Republic of Korea

Background: The impact of tissue prolapse (TP) on clinical outcomes after stent implantation is still not well known. We used intravascular ultrasound (IVUS) to evaluate the association of TP with short- and long-term clinical outcomes after stent implantation in 418 acute myocardial infarction (AMI) patients (155 ST segment elevation and 263 non-ST segment elevation MI).

Methods: TP was defined as tissue extrusion through the stent strut at post-stenting. We evaluated the incidences of stent thrombosis, no-reflow, and long-term clinical outcomes.

Results: After stenting, TP was detected in 34% without difference according to the stent types. Acute and subacute stent thromboses occurred more frequently in patients with TP compared with those without TP (3.5% vs. 0.7%, p=0.035, and 4.2% vs. 0.7%, p=0.013, respectively). However, no significant difference was observed in the incidence of late stent thrombosis between both groups. No-reflow was developed more frequently in patients with TP compared with those without TP (25.4% vs. 9.8%, p=0.001). Creatine kinase-MB and cardiac troponin-I were elevated more frequently in patients with TP compared with those without TP (9.0 ± 2.5 U/l vs. 4.2 ± 1.6 U/l, p=0.001 and -10.0 ± 4.3 5 ng/ml vs. -1.2 ± 3.5 ng/ml, p=0.005, respectively). There were no significant differences in the incidences of cardiac death, MI, and target vessel revascularization at 1-year. Multivariate analysis showed that TP was the independent predictor of composite of acute and subacute stent thrombosis (OR=4.211; 95% CI 1.198-14.805, p=0.025) and composite of acute stent thrombosis and no-reflow (OR=2.551; 95% CI 1.315-4.952, p=0.006).

Conclusion: TP was associated with short-term complications (acute and subacute thrombosis and no-reflow phenomena), however it was not affect long-term clinical outcomes after stent implantation in patients with AMI.

TCT-106 Fate of Side Branches at 6, 12 and 24 months after implantation of Biosorbable Scaffolds: Assessment with 3-dimensional optical coherence tomography

Yoshinosuke Onuma1, Maria Radu2, Robert-Jan van Geuns3, Jacques Koolen1, Leif Thuesen4, Stephan Windeker5, Robert Whitbourn6, Dougall McClean3, Hector M Garcia-Garcia7, John Ormiston8, Patrick W Serruya9
1Thorax Centre, Rotterdam, Netherlands; 2Catharina Ziekenhuis, Eindhoven, Netherlands; 3Shef ’y Systech, Aarhus, Denmark; 4Swiss Cardiovascular Centre, Bern, Switzerland; 5Vincents Hospital, Fitzroy, Australia; 6Christchurch Hospital, Christchurch, New Zealand; 7Cardalysts, Rotterdam, Netherlands; 8Auckland city hospital, Auckland, New Zealand

Background: Fully biosorbable everolimus-eluting vascular scaffolds (ABSORB, Abbott Vascular, Santa Clara, USA) are a novel approach to treat coronary stenosis. However the outcome of jailed side branch with ABSORB has not been investigated yet. The purpose of this study is to assess the fate of struts covering the ostium of side-branches at 6, 12 and 24 months after implantation of the BVS with three-dimensional (3-D) optical coherence tomography (OCT) reconstruction.

Methods: The ABSORB Cohort B trial is a single-arm trial to assess the safety and performance of the BVS. The first 45 patients (Group 1) underwent invasive imaging at 6 months and at 2 years, while the remained 56 patients (Group 2) underwent imaging follow-up at 1 and will repeat it at 3 years. FD-OCT imaging (C7X system) are obtained at a pullback speed at a 20 mms.

Results: Paired 3D images at baseline and 6 months were available in 16 side branches, while paired analysis at baseline and 12-month follow-up were available in 17 side branches. At 6 months, the average ostium area free from jailing struts did not change from baselines (BL: 1.73 ± 1.35 mm², FU: 1.64 ± 1.21 mm², p=0.7), and the number of compartments was similar between baseline and 6 months following implantation (BL: 2.07±1.1, 6M: 1.93±1.0, p=0.16). At 12 months, 3D OCT showed that membranous tissue covers some struts, which was translated into a significant decrease in the number of compartments from 2.1 ± 0.8 at baseline to 1.4 ± 0.85 at 12 months (p=0.005). This was accompanied by a decrease in the strut-free ostial area (BL: 1.89 ± 1.21 mm², 6M: 1.93 ± 1.21 mm², p<0.001). Creatine kinase-MB and cardiac specific troponin-I were elevated more significantly after stenting in patients with TP compared with those without TP (25.4% vs. 9.8%, p<0.001). Among patients with TP compared with those without TP (3.5% vs. 0.7%, p=0.035, and 4.2% vs. 0.7%, p=0.013, respectively). However, no significant difference was observed in the incidence of late stent thrombosis between both groups. No-reflow was developed more frequently in patients with TP compared with those without TP (25.4% vs. 9.8%, p=0.001). Creatine kinase-MB and cardiac troponin-I were elevated more frequently in patients with TP compared with those without TP (9.0 ± 2.5 U/l vs. 4.2 ± 1.6 U/l, p=0.001 and -10.0 ± 4.3 5 ng/ml vs. -1.2 ± 3.5 ng/ml, p=0.005, respectively). There were no significant differences in the incidences of cardiac death, MI, and target vessel revascularization at 1-year. Multivariate analysis showed that TP was the independent predictor of composite of acute and subacute stent thrombosis (OR=4.211; 95% CI 1.198-14.805, p=0.025) and composite of acute stent thrombosis and no-reflow (OR=2.551; 95% CI 1.315-4.952, p=0.006).

Conclusion: The 3-D analysis showed that the ostial area free of struts remained unchanged at 6 months compared to baseline, while it was reduced at 12 months due to growing tissue covering the struts. The results of 2-year imaging will be presented at the time of meeting.

TCT-107 Prevalence, Distribution, Predictors, and Outcomes of Calcified Nodules in Native Coronary Arteries: A Three-Vessel Intravascular Ultrasound Analysis from PROSPECT

Yingxia Xu1, Gary S Mante2, Anthony Tan2, John McPherson3, Andries Grégoire4, Jean Fujalde1, Martin Fab5, Giona Weisz6, Bernard De Bruyne7, Patrick W Serruya8, Gregg W Stone2, 9, Akiko Machara1, 2
1Cardiovascular Research Foundation, New York, NY; 2New York–Presbyterian Hospital, New York, NY; 3Vanderbilt University Medical Center, Nashville, TN; 4Cardiovascular Center, Onze-Lieve-Vrouweziekenhuis, Aalst, Belgium; 5Erasmus University, Rotterdam, Netherlands; 6Hospital Mexicoorio, Vigo, Spain; 7Clinique Pasteur, Toulouse, France

Background: Pathologic studies suggest that calcified coronary nodules account for 2-7% of thrombotic events. The frequency, distribution, predictors, and outcomes of calcified nodules detected in vivo have never been described.

Methods: Following successful stenting in 697 patients with acute coronary syndromes (ACS), three-vascular grayscale and virtual histology (VH) intravascular ultrasound (IVUS) was performed. Based on histologic validation, an independent core lab identified calcified nodule as irregular and convex plaque shape. Patients were followed for three years.

Results: Overall, 314 calcified nodules were detected in 250 of 1573 analyzable arteries (185 of 623 patients). Thus, the prevalence of calcified nodules was 17% per artery and 30% per patient. The location of the calcified nodules were <40mm of the ostium of the coronary arteries in 85% of LAD and 86% of LCX while calcified nodules within the RCA were evenly and more distally distributed. Patients with calcified nodules were significantly older, had more plaque volume (IVUS), and more thick-capped fibroatheroma (VH-IVUS), but fewer non-culprit lesion major adverse events on follow-up.

Conclusion: The 3-D analysis showed that the ostial area free of struts remained unchanged at 6 months compared to baseline, while it was reduced at 12 months due to growing tissue covering the struts. The results of 2-year imaging will be presented at the time of meeting.

TCT-108 Intravascular Shuntography for Immediate Control and Improvement of Results of Coronary Bypass Surgery

Bagrat Alekian, Leo Bockeria, Narek Zacharian, Anton Stafevor, Karen Petrosian, Andre Abrosimov
Bakoulev Scientific Center for Cardiovascular Surgery, Moscow, Russian Federation

Background: To analyze our experience with intravascular shuntography for immediate evaluation of coronary shunts condition in patients after CABG.

Methods: The study comprised 1084 patients who received 2707 coronary shunts during the period from February 2009 through April 2011. The patients’ age varied...
from 41 to 78 years (mean 59.7±4.3). Mean number of shunts per patient was 2.5. All 2707 shunts were distributed as follows: 977 (36%) autovascular shunts using internal mammary artery to the system of the left coronary artery (LAD and DB); 998 (37%) coronary shunt occlusions. In 100 (34.6%) repeated interventions with subsequent shunt occlusions, in 24 (8%) – native artery occlusions and in 16 (6%) – mammaro-coronary shunt occlusions. In 100 (34.6%) cases the stenoses of mammaro-coronary shunt were revealed, in 40 (14%) – venous shunts beyond the shunted artery or the native artery beyond it the degree of stenosis varied from 50 to 90%. In 56 (19%) patients, hence, the rate of complications as calculated for the totality of shunts is 5.8%. Intraoperative shuntography can reveal certain technical problems related to immediate shunts performance, which can lead to early angina recurrence and shunts occlusion in early postoperative period. Intraoperative solution of these problems contributes to the improvement of immediate as well as of long-term results of aortocoronary bypass surgery.

TCT-109
Arterial Response to Sirolimus Eluting Stents with Bioabsorbable Polymer: First IVUS Report from the DESSOLVE-I FIM Trial
Kenji Sakamoto1, Katsumi Waseda1, Paul G Yock1, Yasuhiko Honda1, William Wijns2, John Ormiston1, Peter J Fitzgerald1
1Stanford University Medical Center, Stanford, CA; 2OLY Hospital, Aalst, Belgium; 1Auckland City Hospital, Auckland, New Zealand

Background: The MiStent consists of a cobalt chromium stent with a PLGA bioabsorbable polymer and sirolimus, enabling complete drug elution and polymer absorption within 90 days. DESSOLVE-I is a single-arm, multicenter, first-in-man trial, enrolling 30 patients with follow-up at 4, 6, or 8 months (10 patients each) and 18 months (all). This study aimed to evaluate initial arterial response to MiStent in de novo human coronary lesions.

Methods: In the 4-month cohort, volume index (VI: volume/length) was serially obtained in 10 patients. Neointima obstruction was calculated as neointima/stent volume. Cross-sectional narrowing (CSN) was defined as neointima/stent area. Gross coverage of struts was assessed as neointima-free frame ratio (number of frames without neointima/total frame number).

Results: No significant changes were observed in vessel, plaque, or lumen VI during follow-up. Neointima at 4 months was minimum, and no case showed significant lumen encroachment. Neointima-free frame ratio was 20.2±16.6% (Cypher: 64±26% and Xience: 39±27% at 8-9 months in historical database), indicating the large part of the MiStent covered by neointima at 4 months. One case had late-acquired incomplete stent apposition. There was no target lesion revascularization, cardiac death or stent thrombosis.

Baseline 4 months P value
Vessel VI (mm²/mm) 14.1±4.6 13.7±3.6 0.52
Plaque VI (mm²/mm) 7.3±3.0 6.8±2.5 0.38
Lumen VI (mm²) 6.8±1.7 6.8±1.3 0.16
Minimum lumen area (mm²) 6.0±1.5 5.5±1.1 0.12
Neointimal obstruction (%) NA 5.2±3.2 NA
Maximum CSN (%) NA 11.9±4.6 NA
Stents with max CSN>50% (%) NA 0 NA
Neointima-free frame ratio (%) NA 20.1±16.6 NA
* p value for post procedure vs. 4 months

Conclusion: Preliminary IVUS results from the first-in-man trial showed that the MiStent with sirolimus and bioabsorbable polymer had rapid and uniform neointimal coverage with no adverse vessel reaction. Follow-up of 6 and 8-month cohorts are ongoing.

TCT-110
Follow-Up of Patients with Ostium Secundum Atrial Septal Defect with Severe Pulmonary Arterial Hypertension Undergoing Device Closure
Sudhir Chandra Sinha, Vipperla Sujatha
Department of Cardiology, Indus Hospitals, Visakhapatnam, India

Background: Device closure of Ostium Secundum Atrial Septal Defect (OSASD) is done in patients with Pulmonary artery systolic pressure(PASP) less than 2/3rd of systemic arterial systolic pressure(SASP).Little is known about device closure in patients with OSASD who have PASP>2/3rd of SASP.

Methods: During August 2007 and December 2010, we attempted device closure of 94 patients, between age group 4 years to 60 years. Out of 94, 9 patients had PASP>2/3 rd of SASP. We used only clinical scoring system to identify patients for device closure. All patients were pretreated with oral sildenafil for 3 weeks to prior planned catheterization and device closure.

Results: All patients were females the mean age was 42.5±11.5 years (Range 22-57 years). The mean PASP was 93.67±19.97 mmHg(range 72-140 mm Hg) and mean SASP was 120.11±13.20 mmHg(range106-160 mm Hg). All patients had Qp/Qs > 1.51 and R/Rp < 0.25. The mean follow-up PASP was 44.07±17.23 mmHg(range 30-78 mm Hg). More than 50% drop in PASP from baseline was noted in 7 out of 9 patients, with PASP 15 mm Hg in 6 patients and 58 mmHg in 1 patient. Two patients had significant fall in PASP though it remained 65 mm Hg in one patient and 78 mm Hg in another patient. All patients improved from NYHA Class III to Asymptomatic or functional class I. Three patients were noted to have additional respiratory component contributing to the clinical picture. These patients showed dramatic improvement after device closure. The patients received Sildenafil for 6 months or up to normalisation of PASP. Sildenafil was not associated with improvement in clinical outcome.

Conclusion: Device closure in select patients with OSASD and severe PAH is safe and improves PASP, functional class and quality of life.

TCT-111
Mirgaine Visual Aura with or without Headache: Association with Right to Left Shunt and Assessment Following Transcutaneous Closure
M. Khalid Mojadidi, Hamidreza Khessali, Rubine Gevorgyan, Ralph Levinson, Jonathan Tobis
Interventional Cardiology, UCLA School of Medicine, Los Angeles, CA

Background: R to L shunting, usually caused by a patent foramen ovale (PFO), is associated with migraine headache (MH) with aura. There are patients who present with visual aura but deny headaches. It is unclear whether visual aura without headache is a form of migraine (“visual migraine”) or is due to some other transient neurologic dysfunction. This study assesses the prevalence of right to left (R to L) shunt in patients presenting with visual aura and evaluates if aura resolves following closure of PFO.

Methods: Of 590 patients referred to UCLA for potential PFO related conditions, 225 patients had visual aura with or without MH. Patients were assessed for a R to L shunt with Transcranial Doppler. They were evaluated for the presence of MH and/or visual aura and then divided into three groups: 1) Group A (Aura + MH)- Aura during MH or within 60 minutes of MH; 2) Group B (Aura unrelated to MH)- Aura not during MH or within 60 minutes of MH; 3) Group C (Aura only)- visual aura without MH. The frequency of R to L shunt was compared to a control group of 200 unselected patients referred for diagnostic catheterization. 80 patients (approx. 1/3 per group) underwent PFO closure. Residual MH and visual aura were assessed 12 months after the procedure.

Results: The prevalence of R to L shunt in groups A, B, and the control group were 96%, 72%, 67% and 18% respectively. The prevalence was similar in groups B vs. C (p=0.66), but higher in group A due to selection bias. When compared to the control group, the frequency of R to L shunt in all three groups was much higher (p<0.001). 12 months after PFO closure, symptoms of visual aura were completely resolved in 52%, 75% and 80% of patients in groups A, B and C respectively (p=ns).

Conclusion: There is a strong correlation between PFO closure and improvement of aura (with and without MH) suggesting a causative association between the presence of PFO and the aura phenomenon. Since isolated visual aura has a similar prevalence of R to L shunt and responds to the same to PFO closure, it is likely similar in pathophysiology to MH with aura.